Final Results for the year ended 31 December 2020
01 avr. 2021 07h00 HE
|
4D Pharma PLC
Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the...
4D pharma plc公布Blautix第二階段臨床試驗的最新資料
08 nov. 2018 22h07 HE
|
4D pharma plc
Blautix 過敏性腸道綜合症（IBS）第II階段臨床試驗招募了首名患者 英國利茲, Nov. 09, 2018 (GLOBE NEWSWIRE) -- 4D pharma...
4D pharma plc Announces Clinical Update for Blautix Phase II Study
08 nov. 2018 02h00 HE
|
4D pharma plc
First Patient Enrolment in Blautix IBS Phase II Study LEEDS, United Kingdom, Nov. 08, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), (the “Company” or “4D”) a pharmaceutical company leading...
4D公佈公司正研發的新藥Thetanix在第Ib階段臨床試驗中的數據證實對治療克羅恩症兒科患者證實有正面療效，並在發表的文獻中也顯示Thetanix臨床試驗前模式研究中對治療炎症性腸病有強而有力的療效
24 sept. 2018 18h04 HE
|
4D pharma plc
英國利茲, Sept. 25, 2018 (GLOBE NEWSWIRE) -- 訊 - 4D製藥公司（AIM：DDDD），一間研發活性生物治療藥物領域中具領導地位的製藥公司，今天宣布該公司於Thetanix第Ib階段臨床試驗中，證實該新藥對治療克羅恩症兒科患者有積極的成果。 這項試驗已達成它的主目標，即證明Thetanix具有良好的耐受性和安全性。 ...
4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD
24 sept. 2018 02h00 HE
|
4D pharma plc
LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces positive top-line...
期刊Scientific Reports中的論文指出4D Pharma的MRx0004能夠預防嚴重哮喘患者的氣管炎症
14 août 2018 10h12 HE
|
4D pharma plc
數據顯示MRx0004為治療哮喘甚有潛力的新一代藥物 英國利茲, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 間在活性生物治療藥物開發方面具領導地位的製藥公司4D pharma...
Paper in Scientific Reports Highlights Ability of 4D Pharma’s MRx0004 to Protect Against Airway Inflammation in Severe Asthma
14 août 2018 02h00 HE
|
4D pharma plc
Data suggest that MRx0004 is a promising next-generation therapeutic for management of asthma LEEDS, United Kingdom, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical...
4d公佈數據顯示取自人體腸道微生物羣落的細菌單一菌株有望成爲新型hdac抑制劑
30 juil. 2018 08h16 HE
|
4D pharma plc
英國里茲, July 30, 2018 (GLOBE NEWSWIRE) -- 在活體生物治療藥物開發領域佔領導地位的製藥企業4D pharma plc（AIM:DDDD）今日宣佈，公佈數據顯示，人體腸道微生物中特定細菌的單一菌株有望成爲具備治療效果的人體內組蛋白去乙酰化酶（HDAC）抑制劑，這種酶與涉及宿主表觀遺傳變異的疾病領域存在千絲萬縷的關係。 ...
4D Announces Publication of Data Showing Potential of Single Bacterial Strains From the Human Gut Microbiota to Serve as Novel HDAC Inhibitors
30 juil. 2018 02h00 HE
|
4D pharma plc
LEEDS, United Kingdom, July 30, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM:DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of data...